scholarly journals The effects of dopaminergic medication on dynamic decision making in Parkinson's disease

2014 ◽  
Vol 53 ◽  
pp. 157-164 ◽  
Author(s):  
Magda Osman ◽  
Agata Ryterska ◽  
Kash Karimi ◽  
LingLing Tu ◽  
Ignacio Obeso ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Decision Making ◽  
Parkinson's Disease ◽  
Dynamic Decision Making ◽  
Dopaminergic Medication

scholarly journals Dopaminergic drugs decrease loss aversion in Parkinson’s disease with but not without depression

2016 ◽  
Author(s):  
Monique H.M. Timmer ◽  
Guillaume Sescousse ◽  
Rianne A.J. Esselink ◽  
Payam Piray ◽  
Roshan Cools
Keyword(s):  
Parkinson’S Disease ◽  
Decision Making ◽  
Parkinson's Disease ◽  
Loss Aversion ◽  
Drug Effects ◽  
Risky Choice ◽  
Motor Symptom ◽  
Risky Decision ◽  
Dopaminergic Drugs ◽  
Dopaminergic Medication

AbstractDepression, a common non-motor symptom of Parkinson’s disease (PD), is accompanied by impaired decision making and an enhanced response to aversive outcomes. Current strategies to treat depression in PD include dopaminergic medication. However, their use can be accompanied by detrimental side effects, such as enhanced risky choice. The mechanisms underlying dopamine-induced increases in risky choice are unclear. In the current study we adopt a clinical-neuroeconomic approach to investigate the effects of dopaminergic medication on loss aversion during risky choice in depressed and non-depressed PD. Twenty-three healthy controls, 21 depressed and 22 non-depressed PD patients were assessed using a well-established gambling task measuring loss aversion during risky choice. Patients were tested on two occasions, after taking their normal dopaminergic medication (ON) and after withdrawal of their medication (OFF). Dopaminergic medication decreased loss aversion to a greater extent in depressed than non-depressed PD patients. Moreover, we show that the degree to which dopaminergic medication decreases loss aversion correlated with current depression severity and with drug effects on depression scores. These findings demonstrate that dopamine-induced changes in loss aversion depend on the presence of depressive symptoms in PD.Significance statementDopaminergic medication that is used to treat motor and non-motor symptoms in patients with Parkinson’s disease is known to contribute to risky decision-making. The underlying mechanisms are unclear. The present study demonstrates that dopaminergic medication in Parkinson’s disease decreases loss aversion during risky choice, but only in depressed and not in non-depressed patients with Parkinson’s disease. These results advance our understanding of the mechanisms underlying dopamine-induced risky choice, while also identifying depression as an important factor that confers vulnerability to such dopamine-induced risky choice.Conflict of InterestThe authors declare no competing financial interests.

Decision-making under risk is improved by both dopaminergic medication and subthalamic stimulation in Parkinson's disease

2014 ◽  
Vol 254 ◽  
pp. 70-77 ◽  
Author(s):  
Jana K. Boller ◽  
Michael T. Barbe ◽  
K. Amande M. Pauls ◽  
Christiane Reck ◽  
Matthias Brand ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Decision Making ◽  
Parkinson's Disease ◽  
Decision Making Under Risk ◽  
Dopaminergic Medication ◽  
Subthalamic Stimulation

scholarly journals Implications of dopaminergic medication withdrawal in Parkinson’s disease

2021 ◽  
Author(s):  
J. Koschel ◽  
K. Ray Chaudhuri ◽  
L. Tönges ◽  
M. Thiel ◽  
V. Raeder ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopaminergic Medication ◽  
Medication Withdrawal

scholarly journals Bringing Advanced Therapies for Parkinson’s Disease to the Clinic: The Scientist’s Perspective

2021 ◽  
pp. 1-6
Author(s):  
Mark Tomishima ◽  
Agnete Kirkeby
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Trials ◽  
Phase I Clinical Trials ◽  
Preclinical Models ◽  
Preclinical Development ◽  
Dopaminergic Medication ◽  
Gene Therapies ◽  
Advanced Therapies ◽  
New Phase

After many years of preclinical development, cell and gene therapies have advanced from research tools in the lab to clinical-grade products for patients, and today they constitute more than a quarter of all new Phase I clinical trials for Parkinson’s disease. Whereas efficacy has been convincingly proven for many of these products in preclinical models, the field is now entering a new phase where the functionality and safety of these products will need to stand the test in clinical trials. If successful, these new products can have the potential to provide patients with a one-time administered treatment which may alleviate them from daily symptomatic dopaminergic medication.

scholarly journals Risky decision-making and affective features of impulse control disorders in Parkinson’s disease

2017 ◽  
Vol 125 (2) ◽  
pp. 131-143 ◽  
Author(s):  
Alice Martini ◽  
Simon J. Ellis ◽  
James A. Grange ◽  
Stefano Tamburin ◽  
Denise Dal Lago ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Decision Making ◽  
Parkinson's Disease ◽  
Impulse Control ◽  
Impulse Control Disorders ◽  
Risky Decision Making ◽  
Risky Decision

Theory of mind and decision-making processes are impaired in Parkinson's disease

2015 ◽  
Vol 279 ◽  
pp. 226-233 ◽  
Author(s):  
Chunhua Xi ◽  
Youling Zhu ◽  
Yanfang Mu ◽  
Bing Chen ◽  
Bin Dong ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Decision Making ◽  
Parkinson's Disease ◽  
Theory Of Mind ◽  
Decision Making Processes

scholarly journals Influence of Dopaminergic Medication on Conditioned Pain Modulation in Parkinson's Disease Patients

PLoS ONE ◽  
2015 ◽  
Vol 10 (8) ◽  
pp. e0135287 ◽  
Author(s):  
Wiebke Grashorn ◽  
Odette Schunke ◽  
Carsten Buhmann ◽  
Katarina Forkmann ◽  
Sabrina Diedrich ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Pain Modulation ◽  
Conditioned Pain Modulation ◽  
Dopaminergic Medication

scholarly journals Lung Function Testing On and Off Dopaminergic Medication in Parkinson's Disease Patients With and Without Dysphagia

2015 ◽  
Vol 3 (2) ◽  
pp. 146-150 ◽  
Author(s):  
Tareq Sawan ◽  
Mary Louise Harris ◽  
Christopher Kobylecki ◽  
Laura Baijens ◽  
Michel van Hooren ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Lung Function ◽  
Lung Function Testing ◽  
Dopaminergic Medication ◽  
Function Testing
Sign in / Sign up

Export Citation Format

Share Document